Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOM8AL)

• Drug Name: Scopolamine Drug Info
• Synonyms: Atroscine; Euscopol; Hyosceine; Hysco; Isoscopil; Kwells; SEE; Scop; Scopamin; Scopolaminhydrobromid; Scopos; Sereen; Tranaxine; Transcop; Triptone; Atroscine Hydrobromide; Hydroscine hydrobromide; Hyocine F hydrobromide; Hyoscine bromide; Hyoscyine hydrobromide; SCOPOLAMINE BROMIDE; Scopolamine Hyoscine; Scopolaminium bromide; Scopolammonium bromide; Tropane alkaloid; MOLI001381; NCI61806; Borrachero (TN); Burundanga (TN); Hyoscine (TN); L-Hyoscine hydrobromide; Scopoderm-TTS; Scopolamine (INN); Transderm scop (TN); Levo-duboisine (TN); Xy-, (-)-tropate (ester); (-)-Scopolamine hydrobromide trihydrate; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epo; 1alphaH,5alphaH-Tropan-3alpha-ol, 6beta,7beta-epoxy-, (-)-tropate (ester); 3-Oxa-9-azatricyclo(3.3.1.O(sup 2,4))nonan-7-ol, 9-methyl-, tropate (ester); 9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl tropate

Indication

Disease Entry	ICD 11	Status	REF
Addictive disorder	6C50-6C5Z	Approved	[1]
Allergic rhinitis	CA08.0	Approved	[2]
Common cold	CA00	Approved	[2]
Cough	MD12	Approved	[2]
Irritable bowel syndrome	DD91.0	Approved	[2]
Major depressive disorder	6A70.3	Approved	[2]
Mydriasis	LA11.62	Approved	[2]
Nausea	MD90	Approved	[1]
Peptic ulcer	DA61	Approved	[2]
Vasomotor/allergic rhinitis	CA08	Approved	[2]
Iridocyclitis		Investigative	[2]
Uveitis	9A96.Z	Investigative	[2]

• Therapeutic Class: Antispasmodics
• Cross-matching ID:
  PubChem CID: 3000322
  ChEBI ID: CHEMBL16794
  CAS Number: CAS 114-49-8
  TTD Drug ID: DMOM8AL
  VARIDT Drug ID: DR01000

Molecule-Related Drug Atlas

Drug(s) Targeting Muscarinic acetylcholine receptor (CHRM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[5]
Tiotropium	DMFDC0Q	Chronic obstructive pulmonary disease	CA22	Approved	[6]
Darifenacin	DMWXLYZ	Overactive bladder	GC50.0	Approved	[7]
Methylscopolamine	DM5VWOB	Peptic ulcer	DA61	Approved	[8]
Clidinium	DMUMQZ0	Abdominal stomach pain	DD91.4	Approved	[9]
Oxybutynin hydrochloride	DMF2KLU	Urinary incontinence	MF50.2	Approved	[10]
Incruse Ellipta	DM32GSJ	Chronic obstructive pulmonary disease	CA22	Approved	[11]
Revefenacin	DMMP5SI	Chronic obstructive pulmonary disease	CA22	Approved	[12]
Isopropamide iodide	DMQYV60	Allergic rhinitis	CA08.0	Approved	[13]
SUN-101	DMXNZQK	Chronic obstructive pulmonary disease	CA22	Phase 3	[14]

Drug(s) Affected By Microtubule-associated protein 2 (MAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[15]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[16]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[17]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[19]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[20]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[24]

Drug(s) Affected By Neurofilament heavy polypeptide (NEFH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[25]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[18]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[28]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[29]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[30]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[31]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[32]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[33]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor (CHRM)	TTOXS3C	NOUNIPROTAC	Antagonist	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Microtubule-associated protein 2 (MAP2)	OT6UYT3X	MTAP2_HUMAN	Gene/Protein Processing	[4]
Neurofilament heavy polypeptide (NEFH)	OTMSCW5I	NFH_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 330).
• [2] Scopolamine FDA Label
• [3] The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63.
• [4] Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells. PLoS One. 2011;6(11):e27265. doi: 10.1371/journal.pone.0027265. Epub 2011 Nov 11.
• [5] Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
• [6] Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70.
• [7] Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84.
• [8] Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
• [9] Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.
• [10] Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [12] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [13] Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7.
• [14] Long-acting bronchodilators in COPD: Where are we now and where are we going Breathe 06/2014; 10(2):110-120.
• [15] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [16] Establishment of a 13 genes-based molecular prediction score model to discriminate the neurotoxic potential of food relevant-chemicals. Toxicol Lett. 2022 Feb 1;355:1-18. doi: 10.1016/j.toxlet.2021.10.013. Epub 2021 Nov 5.
• [17] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [18] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [19] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [20] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [21] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [22] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [23] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [24] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [25] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [26] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [27] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [28] Tryptanthrin induces growth inhibition and neuronal differentiation in the human neuroblastoma LA-N-1 cells. Chem Biol Interact. 2013 Apr 25;203(2):512-21. doi: 10.1016/j.cbi.2013.03.001. Epub 2013 Mar 13.
• [29] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [30] Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
• [31] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [32] Arsenic metabolites affect expression of the neurofilament and tau genes: an in-vitro study into the mechanism of arsenic neurotoxicity. Toxicol In Vitro. 2007 Sep;21(6):1104-12. doi: 10.1016/j.tiv.2007.04.007. Epub 2007 Apr 27.
• [33] Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.